Side-by-side · Research reference

DSIPvsHGH Fragment 176-191

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticAUTO-DRAFTED8/36 cited

BAnimal-StrongHUMAN-REVIEWED28/59 cited

DSIP

Sleep modulator · Anti-stress

100–200 mcgPer doseSchneider 1986

HumanMechanisticSchneider 1986

HoursHalf-life (est)

SQ · Pre-sleep · Daily during cycle

HGH Fragment 176-191

GH Fragment · Pre-Clinical

50%Weight gain reductionNg 2000

~26 minHalf-life (est.)

No IGF-1 ↑GH axis impact

SQ · IP (animal) · Oral (tested)

01Mechanism of Action

Parameter

DSIP

HGH Fragment 176-191

Primary target

Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986

Beta-3 adrenergic receptors on adipocytesHeffernan 2001

Pathway

Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986

Fragment → β3-AR upregulation → Enhanced lipolytic sensitivityHeffernan 2001

Downstream effect

Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986

Increased lipolysis and beta-3 AR mRNA expression without IGF-1 axis activation

Feedback intact?

—

N/A — does not interact with GH/IGF-1 axis

Origin

Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986

Synthetic peptide derived from hGH residues 176-191; AOD9604 includes N-terminal tyrosine (177-191)Cox 2015

Antibody development

—

Not reported in available studies

02Dosage Protocols

Parameter

DSIP

HGH Fragment 176-191

Standard dose

100–200 mcg SQ pre-sleepSchneider 1986

—

Frequency

Once daily, pre-sleep

Once daily (animal models)

Lower / starter dose

50 mcg pre-sleep

—

Evidence basis

Human-mechanistic + early clinicalSchneider 1986

Animal studies only

Duration

8–12 weeks per cycle

—

Reconstitution

Bacteriostatic water

—

Timing

30–60 min pre-sleep

—

Half-life

Short plasma; CNS effects last hours

—

Animal dose (oral)

—

500 mcg/kg body weightNg 2000

Obese Zucker rats, 19 days.

Animal dose (IP)

—

Not specified (14-day chronic administration)Heffernan 2001

Obese mice, daily IP injection.

Human equivalent dose

—

Not established — no published human RCTs

Duration tested

—

14–19 daysHeffernan 2001 Ng 2000

Detection window

—

50 pg/mL LOD in urine; stable metabolite extends detectionCox 2015

WADA-banned; anti-doping testing available.

Oral bioavailability

—

Demonstrated efficacy in animal oral administrationNg 2000

Potential for oral therapeutic development.

03Metabolic / Fat Loss Evidence

Parameter

DSIP

HGH Fragment 176-191

Primary fat target

—

Adipose tissue (general) — beta-3 AR mediated lipolysisHeffernan 2001

Weight gain reduction

—

50% reduction vs control (15.8 ± 0.6 g vs 35.6 ± 0.8 g)Ng 2000

Obese Zucker rats, 19 days oral administration.

Body fat reduction

—

Significant decrease in body weight and body fat in obese mice (14 days)Heffernan 2001

Lipolytic activity

—

Increased adipose tissue lipolytic activityNg 2000

Direct measurement in treated animals.

Beta-3 AR expression

—

Upregulated β3-AR mRNA in obese mice to lean-comparable levelsHeffernan 2001

Insulin sensitivity

—

No adverse effect — euglycemic clamp confirmedNg 2000

Contrasts with intact hGH diabetogenic effects.

IGF-1 impact

—

No elevation — fragment does not activate GH/IGF-1 axis

Beta-3 AR dependency

—

Effect abolished in β3-AR knockout miceHeffernan 2001

Confirms β3-AR as primary mechanism.

Route of administration

—

Efficacy demonstrated via oral and IP routesNg 2000 Heffernan 2001

Human evidence

—

None published — pre-clinical only

04Side Effects & Safety

Parameter

DSIP

HGH Fragment 176-191

Injection site reaction

Mild irritation

—

Drowsiness

Expected effect (intentional)

—

Vivid dreams

Anecdotally reported

—

Long-term safety

Limited modern RCT data

—

Pregnancy / OB

Avoid

—

Insulin sensitivity

—

No adverse effects observed in euglycemic clamp (animal)Ng 2000

GH/IGF-1 axis

—

No activation — avoids diabetogenic effects of full GHNg 2000

Human safety data

—

Not available — no published human trials

WADA status

—

Banned as performance-enhancing drugCox 2015

Metabolic profile

—

Six metabolites identified; CRSVEGSCG most stableCox 2015

Detection window implications for doping control.

Absolute Contraindications

DSIP

·Pregnancy / breastfeeding
·Concurrent CNS-depressant therapy without supervision

HGH Fragment 176-191

·Competitive athletes (WADA-banned)Cox 2015

Relative Contraindications

DSIP

·Severe sleep apnoea (untreated)
·Concurrent benzodiazepine / opioid use

HGH Fragment 176-191

·Absence of human safety data — experimental use only

05Administration Protocol

Parameter

DSIP

HGH Fragment 176-191

1. Reconstitution

Add 1–2 mL bacteriostatic water to vial.

Subcutaneous injection primary route in research context. Oral administration demonstrated efficacy in animal models at 500 mcg/kg.

2. Injection site

SQ — abdomen. Rotate sites.

Once daily dosing used in animal studies. Timing not specified; GH-independent mechanism suggests flexibility.

3. Timing

30–60 min pre-sleep.

Animal protocols: 14–19 days. Human duration not established — no published trials.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

Lyophilized peptide storage per standard peptide protocols. Metabolite stability suggests refrigerated reconstituted solution viable.

5. Needle

29–31G insulin syringe.

Detectable in urine via SPE-LC-MS at 50 pg/mL LOD. Extended detection window via stable metabolite CRSVEGSCG.Cox 2015